Poolbeg Pharma Plc · LSE:POLB
Poolbeg Pharma — Investor Presentation (November 2021)
21 slides from Poolbeg Pharma's investor presentation, November 2021
Slide 1: Poolbeg Pharma
POOLBEG PHARMA November 2021
Slide 2: Disclaimer
Disclaimer The contents of this presentation and the information which you are given at the time of the presentation have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (the “Act”). Reliance on this presentation for the purpose of engaging
Slide 3: Building a Leading Infectious Diseases Company
Building a Leading Infectious Diseases Company Spun out of Fully funded Significant Shareholders Open Orphan plc £25m raised at IPO July 2021 at IPO & Currently Cathal Friel Schroders Investment Management 7.28% 4.5% Experienced team have Targeting booming infectious Capital light & early Exciting p
Slide 4: Experienced Leadership Team
Experienced Leadership Team Cathal Friel Jeremy Skillington Ian O’Connell Carol Dalton Chairman CEO CFO VP IR & PR • Co-founder & Chairman of • 19 years global industry experience: US, • Financial professional with healthcare & • Co-founder & VP Investor Relations & Open Orphan plc UK, Germany & Ire
Slide 5: Capital Light & Early Monetisation Model
Capital Light & Early Monetisation Model A model that works Big Pharma are looking to in-licence infectious disease products More deals, less in house development The trend for sourcing clinical candidates via in-licensing, acquisition or co-development is continuing to expand The only other company
Slide 6: Booming Infectious Disease Market
Booming Infectious Disease Market Vaccines, Therapeutics, Diagnostics Market expected to exceed $250bn by 2025 Big Pharma seeking products 6
Slide 7: Capital Light & Early Monetisation
Capital Light & Early Monetisation Rapid development to Phase II & frequent partnering / out licencing 1 2 3 Develop assets to Phase II Out licence to Big Pharma which will using Capital Light Approach manage expensive Phase II & III trials Any one deal could generate several Low-cost Phase Cost Res
Slide 8: Poolbeg's Initial Assets
Poolbeg’s Initial Assets 2. In active discussions & 1. POLB 001 actively seeking infectious disease assets to bring into Immuno-modulator treatment our pipeline for further for severe Influenza development No significant upfront payments 3. Infectious disease progression data & bio banks. 4. Predict
Slide 9: POLB 001 - Repositioned for Severe Influenza
POLB 001- Repositioned for Severe Influenza Potential blockbuster Phase II ready treatment for severe influenza • Influenza affects 1 in 8 people annually • Plan to rapidly progress to human proof • 5-10m hospitalised of concept study • ~12% life threatening • Licence / sell to Big Pharma to progres
Slide 10: Vast Array of Human Challenge Study Data & Samples ready to mine using AI
Vast Array of Human Challenge Study Data & Samples ready to mine using AI 300,000 individual samples stored at -80ºC in 22 freezers Flu, RSV, HRV Malaria, SARS-CoV-2 Update October 2021 Partnered with Eurofins Genomics to complete RNA sequencing of RSV samples as a key step in AI Programme Analyze s
Slide 11: Summary
Summary Substantial market opportunity, infectious Capital light & multiple shots on diseases expected to grow to goal clinical strategy in excess of $250bn by 2025 Exciting portfolio, Phase II Entrepreneurial team with ready immunomodulator for many successful exits, created severe Influenza c. $1b
Slide 12: Stay in touch
Stay in touch @PoolbegPharma Poolbeg Pharma Register for RNS news alerts at www.PoolbegPharma.com
Slide 13: Appendix
POOLBEG PHARMA Appendix
Slide 14: Experienced Team to Execute
Experienced Team to Execute Additional team members CMO Liam Tremble Alan Bell Ross Crockett • Industry leading CMO Clinical Operations Project Manager Clinical Development Project Manager Financial Controller - Expert in designing and implementing • BSc honours degree in Immunology, • 14+ years exp
Slide 15: Human Challenge Data - Potential for AI analysis
Human Challenge Data – Potential for AI analysis Human Challenge Study: healthy volunteers are exposed to an infectious agent in a quarantine setting to asses the efficacy of vaccines or treatments Tracking disease progression • hVIVO is a world-leader • Unique data (Day -1) from human challenge stu
Slide 16: PredictViral Biomarker Platform for Predicting Severe Disease
PredictViral™ Biomarker Platform for Predicting Severe Disease Potential to transform the way infectious diseases are treated, opportunity to licence this tool to Big Pharma Further patent applications submitted – October 2021 PredictViral™ Biomarker Diagnostics vs Traditional Diagnosis of Disease A
Slide 17: Unique Vaccine Discovery Platform
Unique Vaccine Discovery Platform Harnessing the human challenge model to discover new vaccines What is an Epitope? • Part of a pathogen that the immune system recognises Step 1. T Cell Generation Step 2. Vaccine Discovery • It is the smallest unit of a molecule required to engage the immune system
Slide 18: POLB 001 - Mechanism of Action
POLB 001 – Mechanism of Action 5 1 Influenza virus infects 4 A high viral burden can cells of the respiratory activate hyperexpression tract of cytokines 1 2 Pattern recognition 5 Inflammatory receptors are activated by cytokines act to self- endosomal and amplify expression 2 cytoplasmic viral anti
Slide 19: POLB 001 - Ideally Suited as a Severe Influenza Therapeutic
POLB 001 – Ideally Suited as a Severe Influenza Therapeutic POLB 001’s ability to interrupt the feedback loop of inflammatory What is p38 MAP Kinase? mediators that result in a ‘cytokine storm’ make it an ideal candidate to reduce disease severity for those most at risk • Central role in regulation
Slide 20: hVIVO's Unique Data & Samples Identified POLB 001
hVIVO’s Unique Data & Samples Identified POLB 001 Comparison of 63 Analyse Severe & Mild Influenza cases • Samples taken from patients with severe Influenza were compared against human challenge study subjects with ‘mild’ Influenza 24 Possible Drug Targets • This work identified 24 potential molecul
Slide 21: Why Reposition Drugs?
Why Reposition Drugs? 1 2 Leverage new, novel disease biology Discovery & development phases insights already completed - reducing spend 3 4 Already proven to be safe, existing Already licenced and trialled in patients clinical safety & efficacy data to be - increased probability of success utilised
Poolbeg Pharma — Investor Presentation (November 2021) on 6ix